News
FBIO
2.760
-8.61%
-0.260
Corbus Pharmaceuticals Holdings Inc. Stock Rises 5.9%, Outperforms Peers
Dow Jones · 2d ago
Journey Medical holds annual shareholder meeting online
PUBT · 3d ago
Fortress Biotech holds annual shareholder meeting
PUBT · 5d ago
Weekly Report: what happened at FBIO last week (0615-0619)?
Weekly Report · 06/22 10:08
Corbus Pharmaceuticals Holdings Inc. Stock Sheds 5.3%, Underperforms Peers
Dow Jones · 06/16 20:34
Weekly Report: what happened at FBIO last week (0608-0612)?
Weekly Report · 06/15 10:09
Corbus Pharmaceuticals Holdings Inc. Stock Rises 5.3%, Outperforms Peers
Dow Jones · 06/12 20:34
Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK
Seeking Alpha · 06/09 09:18
Weekly Report: what happened at FBIO last week (0601-0605)?
Weekly Report · 06/08 10:05
Corbus Pharmaceuticals Holdings Inc. Stock Climbs 8.5%, Outperforms Peers
Dow Jones · 06/04 20:32
Weekly Report: what happened at FBIO last week (0525-0529)?
Weekly Report · 06/01 10:09
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
Seeking Alpha · 05/29 21:20
Corbus Pharmaceuticals Holdings Inc. Stock Slides 30.3%, Underperforms Peers
Dow Jones · 05/26 20:33
Weekly Report: what happened at FBIO last week (0518-0522)?
Weekly Report · 05/25 10:12
Corbus Pharmaceuticals Holdings Inc. Stock Rises 18.3%, Outperforms Peers
Dow Jones · 05/21 20:32
Corbus Pharmaceuticals Holdings Inc. Stock Rallies 6.3%, Outperforms Peers
Dow Jones · 05/20 20:35
Journey Medical CEO joins fireside chat at A.G.P. virtual healthcare conference
PUBT · 05/19 20:45
Corbus Pharmaceuticals Holdings Inc. Stock Slips 8.0%, Underperforms Peers
Dow Jones · 05/19 20:33
Corbus Pharmaceuticals Holdings Inc. Stock Falls 9.8%, Underperforms Peers
Dow Jones · 05/18 20:33
Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), Cardiol Therapeutics (CRDL)
TipRanks · 05/18 13:10
More
Webull provides a variety of real-time FBIO stock news. You can receive the latest news about Fortress Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About FBIO
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.